An update from Lupin Limited ( (IN:LUPIN) ) is now available.
Lupin Limited has announced the incorporation of a wholly-owned subsidiary, LUPINLIFE Consumer Healthcare Limited, aimed at transferring its Over-the-Counter Consumer Healthcare Business. Additionally, the company has reappointed Ms. Vinita Gupta as CEO and Mr. Ramesh Swaminathan as Executive Director and Global CFO, both for further five-year terms. These strategic moves are expected to strengthen Lupin’s position in the healthcare market and enhance its operational efficiency. Furthermore, Lupin plans to implement a new Employee Stock Option Scheme for its eligible employees, subject to necessary approvals.
More about Lupin Limited
Lupin Limited is a global pharmaceutical company based in Mumbai, India, engaged in the manufacturing and development of a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company is focused on the healthcare industry and aims to expand its market presence through strategic initiatives.
YTD Price Performance: -8.25%
Average Trading Volume: 19,249
Current Market Cap: 1004.1B INR
See more insights into LUPIN stock on TipRanks’ Stock Analysis page.